Eurofins CDMO Alphora

What Eurofins CDMO Alphora does

Eurofins CDMO Alphora is a Canadian-based contract development and manufacturing organization (CDMO) headquartered in Mississauga, Ontario, providing integrated end-to-end services for both small molecules and biologics across the drug development lifecycle. The company operates as a wholly-owned subsidiary of Eurofins Scientific SE, a publicly traded life sciences company listed on Euronext Paris (ticker: ERF), and functions within the broader Eurofins CDMO network whose facilities span North America, Europe, and India. Founded in 2003 with 51-100 employees, Alphora serves pharmaceutical and biopharmaceutical clients requiring outsourced drug substance (API) and drug product development and manufacturing.

The company's service portfolio spans preclinical through commercial stages and includes API development and cGMP manufacturing, solid state research, drug product formulation, biologics manufacturing (cell banking, monoclonal antibodies, ADCs, pDNA), sterile and non-sterile manufacturing, fill-finish with lyophilization, clinical trial material packaging and logistics, and regulatory services (IND/IMPD and NDA/CTD). Notable technical capabilities developed through partnerships include a next-generation ADC expression platform created in collaboration with UK-based Daresbury Proteins Ltd. and supported by NRC IRAP funding, as well as custom-built Continuous Flow manufacturing technology for API process intensification developed with a local Ontario university. The company also operates in specialized verticals including oncology HPAPI, cell and gene therapy, cannabinoids, orphan drugs, and pediatrics.

Commercially, Eurofins CDMO Alphora targets pharmaceutical and biopharmaceutical enterprise clients through direct field sales engagement under a B2B model. Revenue is generated through contract manufacturing agreements (project-based and multi-year) and professional development services including formulation, process development, analytical, and regulatory work. Pricing is quote-based and not publicly disclosed, varying by project scope, complexity, regulatory requirements, and contract duration. Customer segmentation is horizontal across pharma and biopharma, with the primary segment being enterprise pharmaceutical and biopharmaceutical companies, and secondary segments in biologics developers and oncology therapeutics developers.

Name

Eurofins CDMO Alphora

Legal name

Eurofins Alphora

Website

https://alphoraresearch.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Eurofins CDMO Alphora is a Mississauga, Ontario-based contract development and manufacturing organization (CDMO) providing integrated API, drug product, and biologics services to pharmaceutical and biopharmaceutical clients, operating as a subsidiary of Eurofins Scientific SE.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development & Manufacturing (CDMO) Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

Keywords

• Contract pharmaceutical manufacturing
• Drug substance development
• Biologics CDMO services
• API manufacturing services
• Pharmaceutical fill finish

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Revenue generated through contract development and manufacturing services for pharmaceutical companies. Services include API development and cGMP manufacturing, drug product manufacturing, and biologics development. Compensation is typically project-based or through multi-year manufacturing agreements with pharmaceutical clients.
2. Development Services: Fees for preclinical and clinical development services including formulation development, process development, regulatory services, and analytical services. These professional services support clients from early development through commercialization.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Eurofins CDMO Alphora is a contract development and manufacturing organization providing integrated end-to-end services for drug substance (API) and drug product for both small molecules and biologics. Services span preclinical through clinical and commercial stages, including API development and cGMP manufacturing, solid state research, drug product formulation, biologics manufacturing (cell banking, pDNA, mAbs, ADCs), sterile and non-sterile fill-finish, clinical trial material packaging, regulatory submission support, and specialized offerings in cannabinoids, pediatrics, and orphan drugs. The company differentiates through a proprietary next-generation ADC expression platform and in-house continuous flow manufacturing technology.

Product overview

Eurofins CDMO is a Contract Development & Manufacturing Organization providing integrated, end-to-end solutions for preclinical and clinical outsourcing services for both Drug Substance/API and Drug Product for Biologics and Small Molecules. The offering is organized as a platform of interconnected service lines spanning: Small Molecules API Development & Manufacturing (with sub-services including API Development, cGMP Manufacturing, Commercialization Support, Fate & Purge, Impurity Synthesis, Process Development, and Fast Track Program); Small Molecules Solid State R&D (Polymorph Screening, Salt/Co-Crystal Screening, Solubility Screening, Chiral Resolution, Crystallization Optimization); Small Molecules DP Development & Manufacturing (Formulation, Highly Potent/Cytotoxics, Micronization, Spray Drying); Biologics DS/DP Development & Manufacturing (Cell Banking, Drug Substance, pDNA, mAbs, ADCs); Cell & Gene therapy; Sterile Manufacturing/Fill & Finish with Lyophilization; Non-Sterile Manufacturing (Liquids, Solids, Semi-solids); Clinical Trial Material Packaging & Logistics; Regulatory Services (IND/IMPD, NDA/CTD); Quality by Design; and specialized verticals including Cannabinoids, Pediatrics, Orphan Drugs, and SynPure LPA. Advanced capabilities include Continuous Flow technology for API intensification. Facilities are strategically located across North America, Europe, and India.

Differentiator

Problem solved

Functional benefit

Products and services

• Small Molecules - API Development & Manufacturing Comprehensive API development and manufacturing services including API Development, API cGMP Manufacturing, API Commercialization Support, Fate & Purge services, Impurity Synthesis, Process Development, and a Fast Track Program for small molecule therapeutics. Designed for pharmaceutical and biopharmaceutical companies outsourcing API development and manufacturing.
• Small Molecules - Solid State Research and Development Solid state characterization services including Physicochemical Characterization, Polymorph Screening, Salt or Co-Crystal Screening, Solubility and Intrinsic Dissolution Screening, Chiral Resolution, and Crystallization Process Development and Optimization for small molecule drug developers.
• Small Molecules - DP Development & Manufacturing Drug product development and manufacturing services including Pre-Formulation/Formulation, Drug Product Development, Highly Potent/Cytotoxics handling, Micronization/Particle Size Reduction, and Spray Drying for small molecule drug product clients.
• Biologics - DS/DP Development & Manufacturing End-to-end biologics development and manufacturing including Cell Banking, Drug Substance, (Pre-)Formulation and Characterization, Biologics Drug Product Development, pDNA manufacturing, Monoclonal Antibodies (mAbs), and Antibody Drug Conjugates (ADCs) for biologic developers.
• Sterile Manufacturing / Fill & Finish Sterile manufacturing services including Lyophilization/Freeze drying cycle for injectable pharmaceutical products.
• Non-Sterile Manufacturing Non-sterile dosage form manufacturing for Liquids, Solids, and Semi-solids.
• Clinical Trial Material, Packaging & Logistics Clinical trial supply services including Primary Packaging, Secondary Packaging & Labeling, QP Services, and GMP Storage & Distribution for clinical-stage pharmaceutical clients.
• Regulatory Services Regulatory submission support including IND/IMPD Services and NDA/CTD Services for drug approvals.
• Cell & Gene Therapy Development & Manufacturing Cell and gene therapy development and manufacturing services for advanced therapy developers.
• Cannabinoids - API/DP Development & Manufacturing Specialized cannabinoid API and drug product development and manufacturing services for cannabinoid-based pharmaceutical developers.
• SynPure LPA - Linear PolyAcrylamide Specialty linear polyacrylamide (LPA) product supplied for pharmaceutical applications.
• Full Clinical CRO and CDMO Package Integrated clinical CRO and CDMO services providing end-to-end drug development support from preclinical through clinical phases.
• ADME, CDMO & OPTIMED Services Absorption, Distribution, Metabolism, and Excretion (ADME) studies combined with CDMO and OPTIMED services for preclinical drug development clients.
• Next-Generation ADC Expression Platform High-yield antibody-drug conjugate (ADC) production platform integrating optimized affinity peptide tags directly into monoclonal antibody production, eliminating traditional conjugation and purification steps to reduce manufacturing complexity and cost while accelerating timelines. Aimed at pharmaceutical and biotech clients developing ADC therapeutics.
• Advanced Continuous Flow Technology for API Manufacturing Advanced continuous flow manufacturing technology for API manufacturing enabling substantial intensification of complex processes traditionally difficult to scale in batch mode, providing enhanced process control, improved safety, and greater production agility from early development through commercial-scale production. Targeted at pharmaceutical clients with complex API manufacturing requirements.

Quantifiable outcome

• Reduces ADC manufacturing complexity and costs while accelerating development timelines
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Local University (Ontario)coreStrategic or Co-development Partner · 16 April 2026Collaboration with a local Ontario university for development of in-house Continuous Flow technology for API manufacturing, enabling substantial intensification of complex manufacturing processes.
• Daresbury Proteins Ltd.coreStrategic or Co-development Partner · 5 February 2026Collaboration with UK-based Daresbury Proteins Ltd. on a research project funded by Canada's NRC IRAP to develop a next-generation ADC (antibody-drug conjugate) expression platform. The platform integrates optimized affinity peptide tags directly into monoclonal antibody production, eliminating traditional conjugation and purification steps.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Piramal Pharma Solutions: CDMO offering integrated API, drug product, and biologics services with particular strength in HPAPI handling and antibody-drug conjugates. Closely comparable to Alphora's HPAPI/oncology and ADC platform focus.
• Thermo Fisher Scientific (Patheon CDMO): Operates one of the world's largest CDMO networks through Patheon, offering integrated small-molecule API, drug product, and biologics services. Directly comparable to Eurofins CDMO Alphora's end-to-end small-molecule and biologics offering and a flagged top-3 capacity investor.
• Lonza Group: Global leader in CDMO services for small molecules, biologics (mAbs, ADCs), and cell & gene therapy. Comparable to Alphora across drug substance and drug product, with leading ADC and biologics capabilities that overlap directly with Alphora's platform focus.
• WuXi AppTec: China-based CRDMO offering end-to-end small-molecule and biologics services including API, drug product, and biologics manufacturing. Comparable to Eurofins CDMO Alphora in integrated service scope and identified as one of three major CDMOs making significant GMP capacity investments.
• Samsung Biologics: Large-scale biologics CDMO specializing in mAb, ADC, and biopharmaceutical manufacturing. Comparable to Alphora's biologics DS/DP and ADC platform focus, though at materially greater scale.
• Catalent (Novo Holdings): Major global CDMO offering drug substance, drug product, fill-finish, and clinical supply services across small molecules and biologics. Overlaps with Alphora's integrated service model and clinical trial material capabilities.
• Hovione: Specialty CDMO with strong capabilities in API development, particle engineering (spray drying, micronization), and drug product manufacturing. Comparable to Alphora in small-molecule API and drug product services, including HPAPI handling.
• Siegfried Holding: Swiss-based CDMO offering API manufacturing, drug product services, and integrated small-molecule solutions. Comparable to Eurofins CDMO Alphora's small-molecule API/DP offering and integrated service model.
• Recipharm: European CDMO providing API and drug product manufacturing, sterile fill-finish, and development services. Comparable across small-molecule API, DP, and sterile fill-finish service lines offered by Alphora.
• AGC Biologics (Asahi Kasei Bioprocess): Global CDMO specializing in mammalian and microbial biologics manufacturing, including mAbs, recombinant proteins, and cell & gene therapy. Comparable to Alphora's biologics DS/DP development and manufacturing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/eurofinscdmo
• LinkedInlinkedin.com/company/alphora-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eurofins CDMO Alphora